These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24782167)

  • 1. Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer.
    Liu D; Wu J; Shi GY; Zhou HF; Yu Y
    Genet Mol Res; 2014 Apr; 13(2):3100-7. PubMed ID: 24782167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
    Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
    Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.
    He C; Duan Z; Li P; Xu Q; Yuan Y
    Anticancer Drugs; 2013 Mar; 24(3):300-5. PubMed ID: 23211354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis.
    Li L; Wan C; Wen FQ
    Genet Mol Res; 2014 May; 13(2):3772-86. PubMed ID: 24938464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
    Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
    Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy.
    Zhang L; Ma W; Li Y; Wu J; Shi GY
    Genet Mol Res; 2014 Jan; 13(1):228-36. PubMed ID: 24446315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
    Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of GSTP1 Ile105Val and XRCC1 Arg194Trp, Arg280His and Arg399Gln gene polymorphisms in the clinical outcome of advanced non-small cell lung cancer.
    Zhao R; Chen G
    Int J Clin Exp Pathol; 2015; 8(11):14909-16. PubMed ID: 26823821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GSTP1 Ile105Val and XRCC1 Arg399Gln gene polymorphisms contribute to the clinical outcome of patients with advanced non-small cell lung cancer.
    Bu L; Zhang LB; Mao X; Wang P
    Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
    Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
    J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy.
    Zou HZ; Zhao YQ
    Genet Mol Res; 2015 Jan; 14(1):500-6. PubMed ID: 25729984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of XRCC1 gene polymorphisms in non-small cell lung cancer cisplatin-based chemotherapy, and their effect on clinical and pathological characteristics.
    Liu HF; Liu JS; Deng JH; Wu RR
    Genet Mol Res; 2016 Dec; 15(4):. PubMed ID: 28081275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
    Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
    Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer.
    Zienolddiny S; Campa D; Lind H; Ryberg D; Skaug V; Stangeland L; Phillips DH; Canzian F; Haugen A
    Carcinogenesis; 2006 Mar; 27(3):560-7. PubMed ID: 16195237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
    Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
    Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer.
    Su D; Ma S; Liu P; Jiang Z; Lv W; Zhang Y; Deng Q; Smith S; Yu H
    Lung Cancer; 2007 May; 56(2):281-8. PubMed ID: 17222938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
    Liao WY; Shih JY; Chang GC; Cheng YK; Yang JC; Chen YM; Yu CJ
    J Thorac Oncol; 2012 Jun; 7(6):973-81. PubMed ID: 22551904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.